poisar

Stocks · News reference

Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028

Benzinga Newsdesk

IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ENTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. SEC EDGAR

    8-K filing — Entera Bio Ltd. (ENTX)

    Filed: 2026-08-18 AccNo: 0001178913-26-004178 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    ENTX